News

Merck & Co. signs $220M macrocyclic peptide deal after hailing ‘next wave of drug discovery’

Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. | Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. has pushed further into the space by penning a $220 million biobucks deal with Unnatural Products.

Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy

The next wave of gene editing advances will likely center not only on efficacy but on the diversity of where the therapies can be delivered, and Genentech is signing a new deal to keep up with the | Roche is the latest large pharma to buy into GenEdit's nanoparticle delivery tech for gene editing therapies, paying $15 million upfront. The biotech previously added Eli Lilly as an investor and inked a partnership with Sarepta.

Marianne Abib Pech, à fonds pour le durable

Après une jolie carrière financière, Marianne Abib Pech a quitté le confort du rond-de-cuir pour se mettre à son compte et tenter de réorienter les investisseurs vers une industrie bien réelle, qui prenne en compte les enjeux environnementaux du XXI e siècle.

Lummus Strengthens Position in Circular Economy

Lummus Strengthens Position in Circular Economy - Investment in Resynergi will scale groundbreaking microwave pyrolysis...

Resynergi Raises $6.4M in Series B Funding Co-led By Transitions First and Lummus Technology To Scale Plastic Recycling Technology

Resynergi, a pioneering leader in plastic recycling technology, announced today it has raised $6.4M in series B funding co-led by Transitions First and Lummus Technology

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology | TechCrunch

ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify the most

Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innovation Fund and ARTIS Ventures

UNP’s AI-enhanced platform creates entirely new drugs by engineering synthetic molecules to mimic nature’s macrocycles...

Male birth control gets another shot with small new trial of non-hormonal pill

There may be hope on the horizon for men who want to have more agency over birth control: YCT-529, a drug candidate that aims to be the first non-hormonal contraceptive pill for men.